Streetbeat News

SPRC

SciSparc Ltd.

Industry

Biotechnology

SciSparc Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include SCI-110 for the treatment of Tourette syndrome, obstructive sleep apnea, and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and epilepsy. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in soft gel capsule form. It also has an agreement with the Sheba Fund for Health Services and Research to examine the potential role of SCI-210 for the treatment of status epilepticus; and The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.

Open

0.22

Mkt cap

2.5M

Volume

203K

High

0.24

P/E Ratio

-0.04

52-wk high

14.22

Low

0.22

Div yield

N/A

52-wk low

0.21

SciSparc Ltd. (NASDAQ:SPRC) has received FDA approval to proceed to a Phase IIb clinical trial for its Tourette Syndrome treatment, SCI-110. This marks a significant milestone in addressing unmet medical needs for TS, with the trial set to assess efficacy, safety, and tolerability in adults.

Portfolio Pulse from Rolando García

October 01, 2024 | 12:09 am

SciSparc has received FDA approval to begin a pivotal Phase IIb trial for its Tourette Syndrome treatment, SCI-110, in the U.S. This follows promising Phase IIa results showing up to 40% reduction in tics.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 1:27 pm

SciSparc has signed a non-binding letter of intent to sell its stake in MitoCareX at a 47% increased valuation since its initial investment. This move could positively impact SciSparc's financial position.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 1:06 pm

SciSparc shares rose following FDA approval to start a Phase IIb clinical trial for SCI-110, targeting Tourette syndrome.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 12:18 pm

SciSparc has received FDA approval to begin a Phase IIb clinical trial for its drug SCI-110, aimed at treating Tourette Syndrome. This marks a significant step forward in the company's drug development process.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 12:18 pm

SciSparc shares rose following the submission of an IND application to the FDA for a Phase IIb trial of SCI-110, aimed at treating Tourette syndrome.

Portfolio Pulse from Benzinga Newsdesk

September 18, 2024 | 8:12 pm

SciSparc has submitted an Investigational New Drug (IND) application to the FDA for a Phase IIb trial of their drug SCI-110, aimed at treating Tourette Syndrome. This marks a significant step in the development of their treatment pipeline.

Portfolio Pulse from Benzinga Newsdesk

September 18, 2024 | 8:10 pm

Clearmind Medicine Inc. has filed an international patent for a combination therapy involving Ibogaine and N-Acylethanolamines, developed in collaboration with SciSparc Ltd. This therapy aims to improve the safety and efficacy of Ibogaine-based treatments for substance use disorders. The patent represents a significant advancement in mental health and addiction treatment.

Portfolio Pulse from Juan Spínelli

September 17, 2024 | 4:31 pm

Intel shares rose 6.9% in pre-market trading due to a strategic collaboration with AWS to advance US-based chip manufacturing. Several other stocks, including Galmed Pharmaceuticals and Smith Micro Software, also saw significant pre-market movements.

Portfolio Pulse from Avi Kapoor

September 17, 2024 | 9:48 am

SciSparc has entered into a second amendment with AutoMax Motors, advancing a $1.85 million loan to the company. This financial move could impact SciSparc's financials and strategic positioning.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2024 | 11:42 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.